Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
38.56 USD   +14.46%
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug

09/28/2022 | 08:59am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
MSCI TAIWAN (STRD) 1.24% 533.406 Real-time Quote.-29.96%
NASDAQ COMPOSITE 4.41% 11468 Real-time Quote.-29.79%
SEAGEN INC. 3.43% 121.39 Delayed Quote.-24.08%
ZAI LAB LIMITED 14.46% 38.56 Delayed Quote.-46.40%
All news about ZAI LAB LIMITED
11/29Hopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rat..
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
11/15Zai Lab Grants American Depositary Shares
MT
11/11Asian ADRs Surge Higher in Friday Trading as China Eases COVID-19 Restrictions
MT
11/11Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating
MT
11/10Asian ADRs Soar in Thursday Trading Following US Inflation Data
MT
11/10Transcript : Zai Lab Limited, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/09Zai Lab's Q3 Net Loss Widens
MT
11/09Zai Lab Reports Wider Q3 Loss, Higher Revenue
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 215 M - -
Net income 2022 -464 M - -
Net cash 2022 967 M - -
P/E ratio 2022 -6,46x
Yield 2022 -
Capitalization 3 233 M 3 233 M -
EV / Sales 2022 10,5x
EV / Sales 2023 5,65x
Nbr of Employees 1 951
Free-Float 97,4%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 33,69 $
Average target price 82,53 $
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Peter Huang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-46.40%3 233
CSL LIMITED4.08%97 598
SAMSUNG BIOLOGICS CO.,LTD.-1.77%47 429
BIOGEN INC.21.46%41 963
WUXI BIOLOGICS (CAYMAN) INC.-45.81%26 444
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-27.40%20 564